Venetoclax-d8
Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
Product Specifications
CAS Number
1257051-06-1
Product Name Alternative
ABT-199-d8; GDC-0199-d8; RG7601-d8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H361, H373
Target
Autophagy; Bcl-2 Family
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4C([2H])([2H])C([2H])([2H])N(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)C([2H])([2H])C4([2H])[2H])C=C3OC7=CN=C(NC=C8)C8=C7
Molecular Formula
C45H42D8ClN7O7S
Molecular Weight
876.49
Precautions
H302, H315, H319, H361, H373
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Bi C, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017 Apr;102 (4) :755-764.|[3]Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124 (25) :3738-47.|[4]Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19 (2) :202-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
